Table 3 IgG antibody avidities to CSP in relation to risk of clinical malaria

From: Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy

 

Avidity

Avidity + Concentration

 

NANP

C-term

NANP

C-term

C-term

C-term

n subjects

691

700

689

700

694

694

Avidity index IgG M3

0.47 (0.23, 0.94)

0.04 (0.01, 0.22)

0.89 (0.43, 1.83)

0.07 (0.05, 0.90)

0.09 (0.02, 0.70)

0.09 (0.03, 0.31)

Concentration NANP IgG M3

–

–

0.54 (0.44, 0.66)

–

0.55 (0.44, 0.70)

0.56 (0.47, 0.67)

Concentration C-term IgG M3

–

–

–

0.70 (0.54, 0.91)

1.00 (0.76, 1.34)

–

Site

      

 Bagamoyo

Ref.

Ref.

Ref.

Ref.

Ref

Ref.

 Kintampo

21.7 (11.7, 40.3)

19.9 (11.2, 35.4)

24.1 (12.9, 44.8)

20.2 (11.4, 35.9)

25.2 (13.6, 46.9)

25.2 (13.6, 47.0)

 Nanoro

35.4 (19.1, 65.7)

32.3 (18.2, 55.9)

43.9 (23.5, 82.0)

36.2 (20.3, 64.8)

45.6 (24.3, 85.4)

45.7 (24.4, 85.3)

Age cohort

      

 5–17 months

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

 6–12 weeks

0.92 (0.75, 1.13)

0.81 (0.65, 1.01)

0.60 (0.47, 0.78)

0.76 (0.61, 0.96)

0.53 (0.41, 0.70)

0.54 (0.41, 0.70)

  1. Hazard ratios (95% confidence intervals) for the first clinical malaria episode during the 12-month follow-up period after the third vaccine dose in relation to IgG antibody avidity index at month (M)3. CSP NANP and C-terminus (C-term) IgG models for RTS,S/AS01E vaccines are provided including avidity index, site and age cohort, with or without adjusting for M3 IgG concentrations of the respective CSP construct and, for C-term, also of the other CSP construct (NANP)
Back to article page